^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ZC3H13 (Zinc Finger CCCH-Type Containing 13)

    i
    Other names: ZC3H13, Zinc Finger CCCH-Type Containing 13, KIAA0853, Xio, Zinc Finger CCCH Domain-Containing Protein 13, DKFZp434D1812
    Associations

    News

    Trials
    1m
    m6A modification and its clinical applications in gynaecological cancer. (PubMed, Apoptosis)
    Due to their diagnostic, prognostic and predictive value, m6A regulators have emerged as promising biomarkers in gynaecological cancers in recent years. This review highlights the role of m6A regulators and critically evaluates their biomarker and clinical potential in gynaecological cancers.
    Review • Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • YTHDC1 (YTH Domain Containing 1) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein) • RBM15 (RNA Binding Motif Protein 15) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    2ms
    Relationship between the Expression of m6A Methyltransferase ZC3H13 Gene and the Clinical Features and Prognosis of Patients with Acute Myeloid Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The expression of ZC3H13 in AML patients may be related to tumor burden and immune function. Patients with high expression of ZC3H13 have poor prognosis, and high expression of ZC3H13 is an independent risk factor for the prognosis of AML patients.
    Retrospective data • Journal
    |
    ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    2ms
    Prognostic potential of N6-methyladenosine methylation-associated genes in lung adenocarcinoma. (PubMed, Transl Cancer Res)
    Our study constructed a novel signature associated with m6A modifications, which can serve as a promising prognostic indicator for LUAD. These findings may provide valuable insights into diagnosis and therapeutic strategies for patients with LUAD.
    Journal
    |
    FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • WTAP (WT1 Associated Protein) • YTHDC2 (YTH N6-Methyladenosine RNA Binding Protein C2) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2) • RBM15 (RNA Binding Motif Protein 15) • VIRMA (Vir Like M6A Methyltransferase Associated) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    2ms
    PLAU regulated by a m6A writer ZC3H13 plays the oncogenic role in oral squamous cell carcinoma. (PubMed, Cytotechnology)
    In summary, these results illustrate that ZC3H13-mediated m6A modification increases PLAU mRNA stability and expression, thereby enhancing OSCC progression. The online version contains supplementary material available at 10.1007/s10616-025-00882-9.
    Journal
    |
    PLAU (Plasminogen Activator) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    4ms
    ZC3H13 Loss Drives Cancer Metastatic Progression by Disrupting m6A RNA Methylation. (PubMed, Cancer Res)
    Treatment with FDA-approved m6A demethylase inhibitors effectively reduced the metastatic capabilities of ZC3H13-deficient cells. Together, these findings provide insights into how the m6A writer complex selectively methylates mRNAs, highlight the pathological consequences of altered writer complex composition in cancer, and reveal therapeutic avenues for patients with metastatic cancer. .
    Journal
    |
    BRCA2 (Breast cancer 2, early onset) • RB1 (RB Transcriptional Corepressor 1) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    5ms
    The role of ZC3H13 in promoting M2 macrophage infiltration via m6A methylation in esophageal squamous cell carcinoma tumor progression. (PubMed, Front Immunol)
    Migration of M0 macrophages was facilitated by CCL5. Our findings elucidate the connection between ZC3H13-mediated m6A modification and M2 macrophage infiltration in the ESCC-TME, resulting in M2 macrophage polarization and increased M2 macrophage infiltration.
    Journal
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CCL5 (Chemokine (C-C motif) ligand 5) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • METTL14 (Methyltransferase 14) • METTL3 (Methyltransferase Like 3) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    6ms
    N(6)-methyladenosine modification of ADGRA3 by ZC3H13 suppresses papillary thyroid cancer cell malignancy by inactivating the PI3K/Akt/mTOR signaling pathway. (PubMed, Discov Oncol)
    This study uncovers a novel regulatory mechanism in which ZC3H13-mediated m6A modification of ADGRA3 suppresses PTC cell malignancy by inhibiting the PI3K/Akt/mTOR pathway. These findings highlight the potential of the ZC3H13/ADGRA3 axis as a therapeutic target for PTC, offering a unique and innovative approach to PTC therapy.
    Journal
    |
    ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    7ms
    ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming. (PubMed, Exp Hematol)
    Mechanistically, ZC3H13 stabilizes FOXP1 expression via m6A methylation, driving metabolic reprogramming. These findings uncover a novel ZC3H13-FOXP1 axis and suggest potential therapeutic targets for AML treatment.
    Journal
    |
    FOXP1 (Forkhead Box P1) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    7ms
    ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer. (PubMed, Cell Death Dis)
    ZC3H13 mediated YTHDF1-dependent m6A modification of SNTB1 promotes the progression of GC by influencing the EMT process. Our study is the first to report the crucial role of ZC3H13 mediated m6A modification in GC, and we believe that ZC3H13 can serve as a potential therapeutic target for GC.
    Journal
    |
    ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    7ms
    A Bioinformatics Analysis on the Subtypes of Hepatocellular Carcinoma Related to RNA Processing Genes to Reveal Prognosis and Immune Microenvironment Features. (PubMed, Dig Dis Sci)
    The work highlights the stratification and prognostic value of RPRGs in HCC patients and reveals immune and mutational characteristics of RPRGs, which may hold great implications for patient management and targeted therapy.
    Journal
    |
    LGALS3 (Galectin 3) • SMAD2 (SMAD Family Member 2) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    8ms
    M6A methyltransferase ZC3H13-mediated downregulation of GPX4 mRNA stability inhibits the progression of kidney renal clear cell carcinoma (KIRC). (PubMed, Cell Immunol)
    ZC3H13 destabilizes GPX4 mRNA in an m6A-dependent manner, thereby repressing KIRC cell proliferation, expediting apoptosis, oxidative stress, and impairing mitochondrial function, which provided a promising therapeutic target for KIRC.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    9ms
    Integration of Bulk and Single-Cell RNA Sequencing to Identify RNA Modifications-Related Prognostic Signature in Ovarian Cancer. (PubMed, Int J Gen Med)
    Half-maximal inhibitory concentrations (IC50) values of 47 drugs like paclitaxel differed between two risk groups...The RT-qPCR demonstrated that the expression of LSM2, LSM4, PUS7, SNRPC, and TUT1 were upregulated in OC, while DCP2, WTAP, and ZC3H13 were downregulated. We constructed an RNA modifications-related prognostic signature that can effectively predict clinical outcomes and therapeutic responses in patients with OC.
    Journal
    |
    DCP2 (Decapping MRNA 2) • WTAP (WT1 Associated Protein) • ZC3H13 (Zinc Finger CCCH-Type Containing 13)
    |
    TP53 mutation
    |
    paclitaxel